POPULAR diabetes and weight loss drugs improve blood sugar and physical health, but they do not change a person’s employment, marital status, or mental well-being, according to a new study. Researchers found that while medications like Ozempic deliver clear medical benefits, those physical gains do not translate into broader social or economic transformations.
The findings come from a working paper published by the National Bureau of Economic Research. University of Chicago economist Robert Kaestner and co-author Cuiping Schiman tracked adults with Type 2 diabetes between 2012 and 2023 using the Medical Expenditure Panel Survey.
Earlier comparisons suggested that people taking these medications had different rates of marriage and employment than non-users. However, those differences disappeared when the researchers followed the same individuals over time before and after starting treatment.
The results indicate that initial differences between groups stemmed from existing social and demographic factors rather than the medication itself. The pattern held consistent whether patients were evaluated after one year or two years on the drug.
The research comes as insurance companies and government health programs evaluate whether to expand coverage for GLP-1 medications. While clinical trials prove the drugs lower cardiovascular risks and reduce weight, policymakers cannot rely on secondary economic returns like increased workforce participation.
Kaestner noted that standard surveys track major life events like getting married or changing jobs, which may miss subtle changes in daily confidence or personal relationships. Further long-term studies will be needed to measure how the medications affect patients using them solely for weight loss.
